Flai (fludarabine, cytarabine, idarubicin) plus low ‐dose gemtuzumab ozogamicin as induction therapy in cd33‐positive aml: Final results and long term outcome of a phase ii multicenter clinical trial

This article is protected by copyright. All rights reserved.

Source: American Journal of Hematology - February 2, 2018 Category: Hematology Authors: Anna Candoni, Cristina Papayannidis, Giovanni Martinelli, Erica Simeone, Michele Gottardi, Ilaria Iacobucci, Filippo Gherlinzoni, Giuseppe Visani, Michele Baccarani, Renato Fanin Tags: Research Article Source Type: research